Press Releases

pSivida to present at Sachs Conference - Boston Boston, MA and Perth, Australia (February 25, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Managing Director, Dr Paul Ashton is making a company presentation in Boston today at the Sachs Associates 7th

pSivida receives first R&D payments from Pfizer Boston, MA and Perth, Australia (February 20, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced the receipt of US$500k as the first quarterly research and development payment from Pfizer under the terms of the exclusive

Commentary and Highlights

- First R&D funding payments from Pfizer to commence
- BrachySil Pancreatic Cancer Study Results
- pSiNutria Business sold to Intrinsiq

pSivida pancreatic cancer results released Boston, MA and Perth, Australia (January 29, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced the results of the Phase IIa clinical trial of BrachySilTM for the treatment of advanced, inoperable pancreatic cancer presented at the

BrachySil in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium Boston, MA and Perth, Australia (January 23, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, today announced that the final results of the recently

pSivida sells pSiNutria to Intrinsiq(UK) Boston, MA and Perth, Australia (January 21, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, and Intrinsiq Materials Cayman Limited today announced that the assets of pSiNutria Limited, a wholly owned subsidiary of